For research use only.

Catalog No.S3041 Synonyms: L-DOPS

Droxidopa Chemical Structure

CAS No. 23651-95-8

Droxidopa (L-DOPS) is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).

Purity & Quality Control

Choose Selective Adrenergic Receptor Inhibitors

Biological Activity

Description Droxidopa (L-DOPS) is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).
Features An artificial amino acid.
Adrenergic Receptor [1]
In vitro

Droxidopa is a pro-drug which has a structure similar to noradrenaline, but with a carboxyl group. Droxidopa can be administered orally, unlike noradrenaline, and after absorption is converted by the enzyme dopa decarboxylase into noradrenaline thus increasing levels of the neurotransmitter which is identical to endogenous noradrenaline. [1] Droxidopa is well tolerated. [2] Droxidopa could exert its pressor effect in three different ways: a) as a central stimulator of sympathetic activity; b) as a peripheral sympathetic neurotransmitter; c) as a circulating hormone. Droxidopa taken alone increases standing blood pressure. [3] Droxidopa can also cross the blood–brain barrier (BBB) where it is converted to norepinephrine and epinephrine from within the brain. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2 cells NGrmfGFHfW6ldHnvckBie3OjeR?= NInxcpQzPCCq NIfFboNC[3SrdnH0bY9vKG:oIHj1cYFvKFC[UjDlfJBz\XO|ZXSgbY4hcHWvYX6gTIVxTzJiKFTQXE0zMSClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gR3lRO0F2IHHmeIVzKDJ2IHjyd{BjgSCudX3pcoV{[2WwdDDhcoFtgXOrczygSWM2OD1yLkCwOEDPxE1? MXqyNFk3PjB2Mx?=

... Click to View More Cell Line Experimental Data

In vivo The acute administration of droxidopa in PVL and BDL rats caused a significant and maintained increase in arterial pressure and mesenteric arterial resistance, with a significant decrease of mesenteric arterial and portal blood flow, without changing portal pressure and renal blood flow. Droxidopa-treated rats also showed a decreased ratio of p-eNOS/eNOS and p-AKT/AKT and increased activity of RhoK in SMA[5].


Animal Research:


- Collapse
  • Animal Models: biliary duct-ligated (BDL) rats
  • Dosages: 25-50 mg/kg
  • Administration: oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO Insoluble
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 213.19


CAS No. 23651-95-8
Storage powder
in solvent
Synonyms L-DOPS
Smiles C1=CC(=C(C=C1C(C(C(=O)O)N)O)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03446807 Not yet recruiting Drug: Droxidopa|Drug: Placebo Oral Tablet Parkinson Disease|Multiple System Atrophy|Progressive Supranuclear Palsy Loma Linda University|H. Lundbeck A/S December 2021 Phase 2
NCT04977388 Recruiting Drug: Droxidopa|Other: Placebo Menkes Disease|Occipital Horn Syndrome Stephen G. Kaler MD|Nationwide Children''s Hospital July 12 2021 Phase 1|Phase 2
NCT03173781 Completed Drug: droxidopa|Drug: Placebo Parkinson''s Disease Colorado Springs Neurological Associates|H. Lundbeck A/S April 2016 Not Applicable
NCT01331122 Withdrawn Drug: droxidopa Gait Disorders Neurologic Chelsea Therapeutics April 2012 Phase 1|Phase 2
NCT01370512 Completed Drug: Droxidopa|Drug: Pyridostigmine Bromide Orthostatic Hypotension Mayo Clinic|National Institute of Neurological Disorders and Stroke (NINDS) November 2011 Phase 2
NCT01354158 Completed Drug: Droxidopa Spinal Cord Injury|Hypotension Bronx VA Medical Center|Chelsea Therapeutics May 2011 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Adrenergic Receptor Signaling Pathway Map

Related Adrenergic Receptor Products

Tags: buy Droxidopa | Droxidopa ic50 | Droxidopa price | Droxidopa cost | Droxidopa solubility dmso | Droxidopa purchase | Droxidopa manufacturer | Droxidopa research buy | Droxidopa order | Droxidopa mouse | Droxidopa chemical structure | Droxidopa mw | Droxidopa molecular weight | Droxidopa datasheet | Droxidopa supplier | Droxidopa in vitro | Droxidopa cell line | Droxidopa concentration | Droxidopa nmr
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID